Professor James N'Dow

Professor James N'Dow
Professor James N'Dow

Professor James N'Dow

Chair in Surgery (Clin)

About

Academic Urology Unit 2nd Floor Health Sciences Building Foresterhill Aberdeen AB25 2ZD

Biography

James N’Dow is Director of the Academic Urology Unit since its establishment in 2001. His research activity spans across evidence synthesis, trials, guideline development, implementation science and the use of big data to complement traditional trial data. He has consistently secured significant funding for research totalling over £43 million over the past 20 years; including being the Coordinator of two large EU IMI funded big data for better outcomes projects. He is Coordinator of the €12M EU IMI funded 5 year project on prostate cancer big data (https://prostate-pioneer.eu/), a large European Multidisciplinary Consortium of 35 partners from 9 countries to harness the power of Big data to inform clinical practice recommendations. He recently successfully coordinated a second €21.3M EU IMI funded large consortium of 36 partners called OPTIMA researching three solid cancers (Prostate, Breast and Lung cancers).

He was Coordinating Editor of the Cochrane Incontinence Review Group and has a track record in delivering NIHR funded national trials in urology. He is co-lead for the recently funded British Association of Urological Surgeons TUF Trials Unit awarded to CHaRT. Appointed Chair of European Association of Urology Guideline Office Board in 2014. Under his leadership, the EAU Guidelines have become the most comprehensive and trusted urological surgical practice guidelines globally, endorsed by 75 countries.

Co-founder and MD of UCAN. UCAN has led 3 fundraising campaigns over the past 15 years, raising over £7 million in philanthropic contributions (cash and in-kind) galvanising the support of the local business community. UCAN funded the opening of the first Urological Cancer Care Centre in Scotland, brought the first robotics surgical system to Scotland as well as contributing £2,517,000 to University of Aberdeen for urological cancer related research. He is also Founder and trustee for Horizons Trust UK charitable trust.

Qualifications

  • MB ChB Medicine 
    1990 - University of Aberdeen 
  • FRCS (Ed) Surgery 
    1994 - Royal College of Surgeons of Edinburgh 
  • MD Medicine 
    1999 - University of Newcastle 
    With Commendation
  • FRCS (Urol) Urology 
    1999 - Royal College of Surgeons of Edinburgh 

Memberships and Affiliations

Internal Memberships

University of Aberdeen (2001 onwards)

University of Newcastle (1994 – 2001)

External Memberships

Fellow, Royal College of Surgeons of Edinburgh

Fellow, Royal College of Surgeons of England

 British Association of Urological Surgeons

 Medical and Dental Defence Union

European Association of Urology

Association of Academic European Urologist

Research

Research Overview

About Urology Trials:

Urology (AUU) has a strong track record of delivering NIHR funded multicentre randomised trials in collaboration with other urologists across the UK as well as uro-gynaecologists and forms a significant proportion of CHaRT’s trial portfolio. Some examples of Urology trials are:

 Image of Trial logos

James N’Dow (AUU Director) and Graeme MacLennan (CHaRT Director) are co-Lead for the British Association of Urological Surgeons TUF Trials Unit 3 year award (starting 2021).

 A unique strength has always been AUU’s willingness to support other clinical academic surgeons as aspiring trialists to develop and lead trials themselves thereby building capacity of senior academic surgeons as Chief Investigators. The BAUS TUF Trials Unit allows AUU and CHaRT to support the Urological Community to mentor and develop the next generation of Urological Surgeon trialists. 

About PIONEER:
A €12M EU IMI funded 5 year project on prostate cancer big data (https://prostate-pioneer.eu/), a large European Multidisciplinary Consortium of 35 partners from 9 countries to encourage the global urological community to harness the power of real world (Big) data to inform clinical practice recommendations in the field of Prostate Cancer.

Nature Reviews Urology Publication – Introducing PIONEER https://rdcu.be/cqUmi

PIONEER presents a unique opportunity to contribute to critical patient focussed Pan-European Prostate Cancer research. PIONEER has prioritised 56 unanswered research questions using Delphi consensus methodology with all key stakeholders involved in the prioritisation exercise. Prostate Cancer patients from Grampian, across the UK and from the EU countries were involved.

The EAU Prostate Cancer Guideline panel and other prostate cancer Key Opinion Leaders were consulted to propose the most critical questions in the field of prostate cancer to be answered using big data. A two round Delphi survey including 73 healthcare professionals and 57 patients participated in round one followed by 49 healthcare professionals and 169 patients (including 53 English; 19 French; 31 German; 53 Italian; 13 Spanish) in round two, twelve additional questions were proposed during this first round. 56 questions were finally prioritised to be “critically important”.

Over the next 5 years, we expect to answer 10 prioritised research questions using federated analytics methodologies. To do this, PIONEER has had to map datasets to a common data model (OMOP) to allow reliable comparisons of outcomes across different datasets and countries (PIONEER has over 90 datasets in the pipeline for onboarding onto the PIONEER platform).

PIONEER is also exploring inclusion of hospital EHR data with Grampian (DaSH) being an early pilot centre. Researchers will only access pseudonymised data and no patient level data will be released from the DaSH environment. The results of this research will inform European Prostate cancer clinical practice guidelines.

About OPTIMA:
OPTIMA is a € 21.3 million European Commission Innovative Medicines Initiative funded research on patients with solid tumours leveraging the power of real world data analytics and artificial intelligence (AI). It is a five-year project, involving 36 partners across 13 countries. OPTIMA’s mission is to design, develop and deliver the first interoperable and GDPR-compliant European real-world oncology data and evidence generation platform. To achieve this ambitious goal OPTIMA will:

  1. Establish a harmonised large scale real-world evidence data platform for prostate, breast and lung cancer with real-world date covering > 200 million people. The platform will be secure, sustainable and interoperable hosting datasets, data analysis tools, federated learning tools, AI algorithms, and electronic decision support tools.
  2. Drive new knowledge generation through advanced analytics and AI-models. OPTIMA will identify and prioritise the main knowledge gaps in prostate, breast and lung cancer. Based on the key unanswered questions in each of the 3 cancer types, OPTIMA will develop specific AI-models to fill knowledge gaps and propose improved guideline recommendations.
  3. Develop electronic shared decision support tools. These tools will be based on computer-interpretable guidelines developed by combining declarative AI and clinical care pathways developed from the leading clinical practice guidelines for prostate, breast and lung cancer. The electronic decision support tools will be interfaced with patient electronic health records (EHR).

OPTIMA aims at personalisation of treatment, encompassing the richness of available data by processing high-dimensional data across datasets and sources, and using deep learning to identify the decisive factors that enable personalised, real-time decisions for each individual patient based on the most accurate and complete weighing of available knowledge. If successful in its objectives OPTIMA will also inform policy on a European level when it comes to the clinical deployment of AI algorithms in healthcare.

As academic coordinator for both PIONEER and OPTIMA, there are unique opportunities to expand evidence generation to include incorporation of real world evidence into the evidence profiles underpinning clinical practice guidelines development. This would further cement the Academic Urology Unit and the EAU as leaders in the methodologies of Clinical Practice Guidelines development by incorporating real world data analytics and new evidence informed by AI models.

About Clinical Practice Guidelines and Implementation Science:
Whilst the development and global dissemination of evidence based guidelines was transformative for urological practice, it was clear that adherence to guideline recommendations was still suboptimal and there were potentially a myriad of reasons for non-adherence:

IMAGINE (IMpact Assessment of Guidelines Implementation and Education):
IMAGINE is a Pan-European National Urological Society Implementation Science Collaborative established to monitor clinical practice variation across over 40 European countries, to monitor baseline adherence to guideline recommendations and to identify determinants of non-adherence. IMAGINE will go on to develop knowledge transfer interventions geared to improve adherence. The first pilot has seen adherence data capture relating to treatment of over 6000 patients. To find out more on IMAGINE’s objectives, please see the following editorial and a recent publication. 

Improving guideline adherence in urology  2021 - Accepted/In press European Urology Focus

MacLennan, S., Duncan, E., Skolarus, T. A., Roobol, M. J., Kasivisvanathan, V., Gallagher, K. M., Gandaglia, G., Sakalis, V., Smith, E. J., Plass, K., Ribal, M. J., N'Dow, J., Briganti, A.: 

Research Areas

Applied Health Sciences

Supervising

Collaborations

Extensive collaborations across the world.

National – well connected with Urologists across the UK and strong links with the British Association of Urological Surgeons.

International – having spearheaded the engagement and endorsement of the European Urological clinical practice guidelines by National Urological Societies in 75 countries between 2014 – 2021, a strong network exists across all continents around the globe. As adjunct Secretary General of the EAU responsible for Education, I meet with representatives of all European National Urological Societies few times a year to discuss shared interests and collaborative opportunities.

PIONEER Partners:

1

STICHTING EUROPEAN UROLOGICAL FOUNDATION

EAU

Netherlands

2

LUNDS UNIVERSITET

LU

Sweden

3

UNIVERSITA VITA-SALUTE SAN RAFFAELE

USR

Italy

4

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Erasmus MC

Netherlands

5

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

UKE

Germany

6

TAMPEREEN KORKEAKOULUSAATIO SR

TAU

Finland

7

KING'S COLLEGE LONDON

KCL

United Kingdom

8

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

EORTC

Belgium

9

TTOPSTART BV

TTOP

Netherlands

10

INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT LTD

ICHOM

United Kingdom

11

EUROPEAN CANCER PATIENT COALITION

ECPC

Belgium

12

ASSOCIATION EISBM

ASSOC EISBM

France

13

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Imperial

United Kingdom

14

THE HYVE BV

The Hyve

Netherlands

15

EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL

EAPM

Belgium

16

PINSENT MASONS LLP

PM

United Kingdom

18

WEIZMANN INSTITUTE OF SCIENCE

WEIZMANN

Israel

19

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

UoA

United Kingdom

20

TECHNISCHE UNIVERSITAET DRESDEN

TUD

Germany

21

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Fraunhofer

Germany

22

GOETEBORGS UNIVERSITET

UGOT

Sweden

23

STICHTING RADBOUD UNIVERSITEIT

RUMC

Netherlands

24

IHE, INSTITUTET FOR HALSOOCH SJUKVARDSEKONOMI AKTIEBOLAG

IHE

Sweden

25

BAYER AKTIENGESELLSCHAFT

Bayer AG

Germany

26

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

SAN

France

28

ASTELLAS PHARMA EUROPE BV

ASTELLAS

Netherlands

29

NV SAS INSTITUTE SA

SAS

Belgium

30

JANSSEN PHARMACEUTICA NV

JANSSEN

Belgium

31

COVANCE LABORATORIES LTD

COVANCE

United Kingdom

32

ORION OYJ

ORION

Finland

33

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

IQVIA

United Kingdom

34

THE ECANCER GLOBAL FOUNDATION

eGF-eCancer

United Kingdom

35

JULIUS CLINICAL RESEARCH BV

Julius Clinical

Netherlands

36

ASTRAZENECA AB

AstraZeneca

Sweden

37

HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV

HZDR

Germany

 OPTIMA Partners:

1. Stichting EAU Foundation for Urological Research (EAU) NL
2. Lund University (LU) SE
3. Erasmus Universitair Medisch Centrum Rotterdam (EMC) NL
4. Association EISBM (EISBM) FR
5. The University Court of the University of Aberdeen (UoA) UK
6. Tartu Ülikool (TU) EE
7. Universita Vita-Salute San Raffaele (UNISR) IT
8. Queen Mary University of London (QMUL) UK
9. CASUS, Helmholtz-Zentrum Dresden - Rossendorf (HZDR) DE
10. Helios Klinikum Emil von Behring (HC) DE
11. Uppsala University (UU) SE
12. Oxford University (UOXF) UK
13. University of Vienna (UNIVIE) AT
14. European Institute of Oncology (IEO) IT
15.Ludwig-Maximilians-University Munich (LMU) DE
16. University College London (UCL) UK
17. European Organisation for Research and Treatment of Cancer (EORTC) BE
18. Institut de Cancerologie de l’Ouest (ICO) FR
19. Maastricht University (MU) NL
20. Institut Universitari d’Investigacio en Atencio Primaria (IDIAPJGol) ES
21. European Respiratory Society (ERS) CH
22. German Cancer Society (DKG) DE
23. European Lung Foundation (ELF) UK
24. European Cancer Patient Coalition (ECPC) BE
25. ttopstart (TTOP) NL
26. GMV Soluciones Globales de Internet SAU (GMV) ES
27. Information Technology for Translational Medicine (ITTM) LU
28. SmartReporting GMBH (SR) DE
29. Owkin (OWK) FR
30. Arttic Innovation (ART) DE
31. YDEAL software PT
32. Pfizer UK
33. Bayer AG DE
34. Amgen CH
35. Roche CH
36. Abbvie US

Funding and Grants

2004 – 2009

NCCHTA

Conservative treatment for urinary incontinence in men after prostate surgery (MAPS Trial)

 

 

£1,252,961

 

2004 – 2007

BUPA Foundation

Prospective collaborative study of patients with intestinal segments transposed into the urinary tract following surgery for bladder cancer or benign end-stage bladder disease (OTIS Study)

 

£179,857

 

2005 – 2006

NCCHTA

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement (BPE)

 

 

£108,410

 

2006 - 2009

NCCHTA

Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial of antibiotic and antiseptic impregnated urethral catheters.

 

 

£1,323,470

 

2007 - 2009

NCCHTA

Systematic review and economic modelling of the effectiveness and efficiency of non-surgical treatments of women with stress urinary incontinence (SUI)

 

 

£204,031

 

2010 – 2013

NIHR HTA

'Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker (nifedipine) and an alpha blocker (tamsulosin)' (SUSPEND)

 

£1,452,458

 

2010 – 2015

NIHR

Cochrane Incontinence Review Group Editorial Base Funding

 

£590,000

 

2012 – 2015

NIHR

Systematic review and economic modelling of ablative therapy for men with localised prostate cancer

 

£292,253

 

2012 – 2015

CRANES

Development of core outcomes for surgical management of localised prostate cancer to support decision-making by patients, clinicians and policy makers

 

£176,903

 

2013 – 2015

Macmillan Cancer Support

Cancer Survival, Work and Working Life: Developing a Patient Advice & Information System for Scotland

 

£106,000

 

2013 – 2016

Prostate Cancer UK

Extending the UCAN model of patient information and support to remote and rural communities

 

£229,134

 

2013 – 2016

NIHR HTAP

TISU Trial: A multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic retrieval, for ureteric stones

 

£1,426,755

 

2012 – 2017

NIHR HTAP

OPEN Trial: A multicentre randomised controlled trial of urethroplasty versus optical urethrotomy for recurrent bulbar urethral stricture disease

 

£1,324,614

 

2013 – 2016

NIHR HTAP

ANTIC Trial: A multicentre randomised controlled trial of antibiotic prophylaxis for clean intermittent self catheterisation

 

£1,821,671

 

2014 – 2020

NIHR HTAP

PHOTO Trial: A multicentre randomised controlled trial of Photodynamic guided treatment for bladder cancer

 

£2,380,539

 

 

2018 – 2023

 

NIHR HTAP

 

CATHETER II Trial: Randomised Controlled Trial CompAring THE Clinical And CosT-Effectiveness Of VaRious Washout Policies Versus No Washout Policy In Preventing Catheter Associated Complications In Adults Living With Long-Term Catheters

 

£2,270,000

 

2018 – 2023

 

 

 

 

2021 - 2026

European Commission Innovative Medicines Initiative

 

European Commission Innovative Medicines Initiative

 

 

PIONEER: European Network of Excellence for Big Data in Prostate Cancer

 

 

 

 

Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence

€12,000,000

 

 

 

 

 

€21, 300,000

Teaching

Non-course Teaching Responsibilities

Trainer of East of Scotland Urology Specialist Registrars.

Provide research training to medical students as part of the Aberdeen Summer Research Scholarship programme (ASRS).

PhD supervisor.

Trainer and mentor of young academic urological surgeons in evidence synthesis methodology and real world data analytics.

Responsible for Education portfolio of European Association of Urology that has a membership of 19,000 urological surgeons.

Publications

Page 1 of 16 Results 1 to 10 of 157

  • The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer

    Beyer, K., MacLennan, S., Moris, L., Lardas, M., Mastris, K., Hooker, G., Greene, R., Briers, E., Omar, M. I., Healey, J., Tripathee, S., Gandaglia, G., Venderbos, L. D., Smith, E. J., Bjorkqvist, J., Asiimwe, A., Huber, J., Roobol, M. J., Zong, J., Bjartell, A., N’Dow, J., Briganti, A., MacLennan, S., Van Hemelrijck, M., Smith, E. J., N'Dow, J., Plass, K., Ribal, M., Mottet, N., Shepherd, R., Van den Broeck, T., Willemse, P., Campi, R., Gacci, M., Evans-Axelsson, L. S., Crosti, D., Meoni, M., Garzonio, R., Bangma, C., Roobol, M., Remmers, S., Tilki, D., Auvinen, A., Murtola, T., Visakorpi, T., Talala, K., MacLennan, S., Thomas, C., Payne, S., Thompson, L., PIONEER Consortium
    European Urology Focus
    Contributions to Journals: Articles
  • The key role of patient Involvement in the Development of Core Outcome sets in prostate cancer

    Beyer, K., MacLennan, S., Moris, L., Lardas, M., Lardas, M., Mastris, K., Hooker, G., Greene, R., Briers, E., Omar, M. I., Healey, J., Tripathee, S., Gandaglia, G., Venderbos, L. D., Smith, E. J., Bjorkqvist, J., Asiimwe, A., Huberm, J., Roobol, M. J., Zong, J., Bjartell, A., N'Dow, J., Brigantii, A., MacLennan, S., Van Hemelrijck, M., The PIONEER Consortium
    European Urology Focus
    Contributions to Journals: Articles
  • Improving guideline adherence in urology

    MacLennan, S., Duncan, E., Skolarus, T. A., Roobol, M. J., Kasivisvanathan, V., Gallagher, K. M., Gandaglia, G., Sakalis, V., Smith, E. J., Plass, K., Ribal, M. J., N'Dow, J., Briganti, A.
    European Urology Focus
    Contributions to Journals: Articles
  • Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021

    Van Poppel, H., Roobol, M. J., Chapple, C. R., Catto, J. W., N'Dow, J., Sønksen, J., Stenzl, A., Wirth, M.
    European Urology
    Contributions to Journals: Review articles
  • What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?

    Dunsmore, J., Duncan, E., Mariappan, P., de Bruin, M., MacLennan, S., Dimitropoulos, K., Kasivisvanathan, V., Mostafid, H., Briganti, A., N'Dow, J., MacLennan, S.
    BJU International, vol. 128, no. 2, pp. 225-235
    Contributions to Journals: Articles
  • Shockwave Lithotripsy Versus Ureteroscopic Treatment as Therapeutic Interventions for Stones of the Ureter (TISU): A Multicentre Randomised Controlled Non-inferiority Trial

    Dasgupta, R., Cameron, S., Aucott, L., MacLennan, G., Thomas, R., N'Dow, J., Norrie, J., Anson, K., Keeley Jr, F. X., MacLennan, S., Starr, K., McClinton, S.
    European Urology, vol. 80, no. 1, pp. 46-54
    Contributions to Journals: Articles
  • A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research

    Bates, A. S., Ayers, J., Kostakopoulos, N., Lumsden, T., Schoots, I. G., Willemse, P. M., Yuan, Y., van den Bergh, R. C. N., Grummet, J. P., van der Poel, H. G., Rouviere, O., Moris, L., Cumberbatch, M. G., Lardas, M., Liew, M., Van den Broeck, T., Gandaglia, G., Fossati, N., Briers, E., De Santis, M., Fanti, S., Gillessen, S., Oprea-Lager, D. E., Ploussard, G., Henry, A. M., Tilki, D., van der Kwast, T. H., Wiegel, T., N'Dow, J., Mason, M. D., Cornford, P., Mottet, N., Lam, T. B. L.
    European Urology Oncology, vol. 4, no. 3, pp. 405-423
    Contributions to Journals: Review articles
  • Benefits and harms of conservative, pharmacological, and surgical management options for women with bladder outlet obstruction: A systematic review from the European Association of Urology non-neurogenic female LUTS guidelines panel

    Peyronnet, B., Omar, M. I., O'Connor, E., Tzelves, L., Riogh, N. A. A., Manso, M., Yuan, C., Arlandis, S., Bo, K., Costantini, E., Farag, F., Groen, J., Nambiar, A., Phe, V., Van der Vaart, H., N'Dow, J., Harding, C., Lapitan, M. C.
    EAU21 Virtual Congress, pp. S437-S438
    Contributions to Journals: Abstracts
  • Evaluating Patient-Reported Outcomes Measures (PROMs) for localised prostate cancer: A systematic review using the Consensus-based Standard for the selection of health Measurement Instruments (COSMIN) methodology

    Ratti, M. M., Gandaglia, G., Leardini, L., Mazzoleni, F. S., Sisca, E. S., Derevianko, A., Furnari, S., Beyer, K., Pellegrino, F., Sorce, G., Scuderi, S., Barletta, F., Cucchiara, V., Omar, M. I., Maclennan, S., Zong, J., Maclennan, S. J., Aiyegbusi, O. L., Van Hemelrijck, M., N'dow, J., Montorsi, F., Briganti, A., ,
    EAU21 Virtual Congress, pp. S430-S431
    Contributions to Journals: Abstracts
  • TISU (Therepeutic Intervention for Stones in the Ureter): ESWL versus Ureteroscopy, a multicentre RCT

    Dasgupta, R., Cameron, S., Aucott, L., Maclennan, G., Thomas, R. E., N'dow, J., Norrie, J., Anson, K., Keeley, F. X., Maclennan, S., Starr, K., Mcclinton, S.
    European Urology, vol. 79, no. S1, pp. S390-S390
    Contributions to Journals: Abstracts
Show 10 | 25 | 50 | 100 results per page

Refine

Books and Reports

Contributions to Conferences

Contributions to Journals